Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.

2.

Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.

Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH 4th.

J Surg Res. 2014 Apr;187(2):412-26. doi: 10.1016/j.jss.2013.10.032. Epub 2013 Oct 21.

3.
4.

Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH 4th.

Surgery. 2013 Dec;154(6):1323-29; discussion 1329-30. doi: 10.1016/j.surg.2013.04.050. Epub 2013 Aug 22.

5.

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.

Wollmann G, Davis JN, Bosenberg MW, van den Pol AN.

J Virol. 2013 Jun;87(12):6644-59. doi: 10.1128/JVI.03311-12. Epub 2013 Apr 3.

6.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

7.
8.

Vesicular stomatitis virus as a treatment for colorectal cancer.

Stewart JH 4th, Ahmed M, Northrup SA, Willingham M, Lyles DS.

Cancer Gene Ther. 2011 Dec;18(12):837-49. doi: 10.1038/cgt.2011.49. Epub 2011 Sep 2.

10.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

11.

Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF, Hiscott J, Lin R.

Mol Ther. 2013 Nov;21(11):2043-53. doi: 10.1038/mt.2013.187. Epub 2013 Aug 28.

12.

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ.

Virology. 2013 Feb 5;436(1):221-34. doi: 10.1016/j.virol.2012.11.014. Epub 2012 Dec 14.

13.

Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.

Shin EJ, Wanna GB, Choi B, Aguila D 3rd, Ebert O, Genden EM, Woo SL.

Laryngoscope. 2007 Feb;117(2):210-4.

PMID:
17204993
14.

Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.

Ebert O, Harbaran S, Shinozaki K, Woo SL.

Cancer Gene Ther. 2005 Apr;12(4):350-8.

PMID:
15565179
15.

Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.

Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ.

J Virol. 2012 Mar;86(6):3073-87. doi: 10.1128/JVI.05640-11. Epub 2012 Jan 11. Erratum in: J Virol. 2013 Feb;87(3):1923.

16.

Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.

Le Boeuf F, Niknejad N, Wang J, Auer R, Weberpals JI, Bell JC, Dimitroulakos J.

Int J Cancer. 2012 Aug 1;131(3):E204-15. doi: 10.1002/ijc.27404. Epub 2012 Jan 11.

17.

Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.

Felt SA, Moerdyk-Schauwecker MJ, Grdzelishvili VZ.

Virology. 2015 Jan 1;474:163-73. doi: 10.1016/j.virol.2014.10.026. Epub 2014 Nov 19.

18.

Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.

Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.

Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.

19.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk